Egypt Infectious Disease Drugs Market Analysis Report 2022 to 2030

Egypt Infectious Disease Drugs Market Analysis

$ 3999

Egypt Infectious Disease Drugs Market valued at $0.33 Bn in 2023, projected to reach $0.49 Bn by 2030 with a 5.77% CAGR. The market is expanding due to factors like aging populations, rising levels of awareness and education, and emerging infectious diseases. The market is dominated by key players like EIPICO, Pharco Pharmaceuticals, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.

ID: IN10EGPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Aneri Parekh

Buy Now

Egypt Infectious Disease Drugs Market Executive Summary

Egypt Infectious Disease Drugs Market valued at $0.33 Bn in 2023, projected to reach $0.49 Bn by 2030 with a 5.77% CAGR.

The Egypt Infectious Disease Drugs Market focuses on the development, production, distribution, and sale of drugs used to treat infectious diseases. This market includes but is not limited to, respiratory infections, gastrointestinal infections, sexually transmitted infections, vector-borne diseases, and emerging infectious diseases. These infections are caused by bacteria, viruses, fungi, and parasites.

The market's dynamics are driven by a variety of factors, including the demand for treatments that are both effective and inexpensive, compliance with regulatory requirements, intellectual property rights, market competition, and the amount of money spent on healthcare. A further factor that contributes to the formation of the market landscape is the ongoing battle against infectious illnesses, which is being waged through programs like antimicrobial stewardship and multinational partnerships.

In 2023, the global market for pharmaceuticals treating infectious diseases was valued at $118.75 Bn. This surge has been attributed to both an increase in diagnoses and government-sponsored public education campaigns about the management and prevention of infectious diseases. A shifting market environment is indicated by the growing degree of generic competition. Long-term improvement requires removing financial barriers and increasing access to therapy, particularly in underdeveloped countries. More industrial research and development will result from this.

EIPICO manufactures about 300 prescription and over-the-counter medications throughout 23 therapeutic areas, including a significant number of infectious disorders. EIPICO produces medications for illnesses that are common in Egypt and Africa, like malaria and schistosomiasis, to precisely meet the demands of these markets. EIPICO has a well-established distribution network throughout Egypt, which ensures that its products are easily accessible to patients.

Egypt infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Growing Awareness and Education: Public awareness campaigns and educational activities raise awareness of infectious diseases and early detection and treatment. Effective medications to manage and control these disorders are in demand as people learn more about them.

Aging Population: The aging population in Egypt increases the prevalence of infectious diseases as older people are more susceptible to them. As a result, there is an increased need for infectious disease medications to fulfill the healthcare demands of the elderly population.

Emerging Infectious Diseases: New or reemerging infectious diseases increase drug demand. Globalization, urbanization, and environmental changes can spread infectious diseases, allowing pharmaceutical companies to develop and market new drugs.

Market Restraints:

Regulatory Obstacles: Strict rules and lengthy approval procedures could prevent innovative medications from entering the market sooner than they should, giving patients and healthcare professionals fewer options.

Economic Constraints: Many patients may find it difficult to obtain necessary prescriptions due to financial restraints, particularly in rural or low-income settings.

Counterfeit Drugs: The ubiquity of false prescriptions in Egypt's pharmaceutical industry is a serious obstacle for producers of real prescription pharmaceuticals. This compromises efficacy in addition to decreasing revenue.

Healthcare Policies and Regulatory Landscape

To safeguard public health, the Egyptian Drug Authority (EDA), a pharmaceutical regulatory body within the Egyptian Ministry of Health (MOH), is in charge of making sure pharmaceutical products are safe and of high quality. Applicants must provide the Egyptian Drug Authority with adequate information from each part demonstrating the product's safety and efficacy for the uses listed in the recommended labeling to be permitted to lawfully market pharmaceutical products in Egypt. The intricate web of documents, departments, and processes involved may ensnare applicants in red tape and ambiguity. Navigating this bureaucratic labyrinth frequently necessitates the expertise of local specialists who are familiar with the peculiarities and practices of the country.

Competitive Landscape

Key Players:

EIPICO
Pharco Pharmaceuticals
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.